Latest Articles
-
Forecast of the Day: Pfizer’s Immunology Drugs Revenue
The first interim efficacy analysis of Phase 2/3 clinical trial evaluating Pfizer and BioNTech’s Covid-19 vaccine candidate showed it to be more than 90% effective seven days after the second dose in preventing infection in participants wit...
-
Why Pfizer’s Covid-19 Vaccine Is Unlikely To Move The Needle For The Stock
Pfizer (NYSE: PFE) and its German partner BioNTech indicated that their Coronavirus vaccine, dubbed BNT162b2, was over 90% effective at preventing Covid-19 infections among volunteers, based on early data from phase 3 trials. The results are surp...
-
Pfizer, Moderna, J&J: How Are Covid Vaccine Stocks Faring?
The odds of getting a Covid-19 vaccine in the near future are improving, with major companies carrying out late-stage clinical trials. Our indicative theme of Coronavirus Vaccine stocks – which includes a diverse set of U.S. based pharma and bi...
-
Gene Therapy Stocks Continue To Underperform. Are They Worth A Look?
Gene therapy – which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery – was a hot trend in the biotech space, but investor interest in the sector appears to have died...
-
Eli Lilly Stock A Better Bet Compared To Pfizer
Pfizer’s stock (NYSE:PFE) has gained 28% since the March 23 lows of this year, in-line with Eli Lilly & Company stock (NYSE:LLY), which has gained 29% of its value. The lockdown in various parts of the world has had a negative impact on...
-
Pfizer Stock Could See More Upside Compared To Roche
Roche’s ADR (OTCMKTS: RHHBY) has gained over 20% since the March 23 lows of this year, while Pfizer (NYSE:PFE) stock has fared much better and gained 35% of its value. The lockdown in various parts of the world has had a negative impact on ...
-
Are Covid Vaccine Stocks Worth Investing In?
The coronavirus pandemic has been good news for investors in pharma companies racing to develop a Covid-19 vaccine. Stock prices for many of the competing companies are trading around record highs. Some examples: Moderna’s (NASDAQ:MRNA) value h...
-
Johnson & Johnson Or Pfizer For Better Returns?
Johnson & Johnson’s stock (NYSE:JNJ) has gained 27% since the March 23 lows, while Pfizer’s stock (NYSE:PFE) is up 16%, both underperforming the broader S&P, which is up 39%. The lockdown in various parts of the world has had a neg...
-
Pfizer Or AbbVie For Better Returns?
Pfizer’s stock (NYSE:PFE) has declined by 11% since early February after the WHO declared the coronavirus a global health emergency, while AbbVie’s stock (NYSE:ABBV) has fared much better and gained 22%. The lockdown in various parts of the...
-
Why Pfizer Looks Undervalued At $38
Pfizer’s stock (NYSE:PFE) has outperformed the broader markets as well as some of its peers over the last few weeks. While Pfizer stock grew 32.5% since the recent lows of March 23, the S&P 500 gained 28.0%. Looking at other pharmaceutical gi...
-
Pfizer Manages 35% Stock Growth Despite Revenue Decline
You don’t expect the stock of a large diversified company like Pfizer (NYSE:PFE) to return 30% in 3 years when the revenue is going down. However, that’s exactly what happened here! Large stock movements without any topline evidence ...
-
Why Moderna Is Clearly Pulling Ahead In The COVID Vaccine Race
[Updated 5/15/2020] Moderna’s Recent Progress Moderna has made significant progress with its Coronavirus vaccine candidate – mRNA-1273 – in recent weeks, as it gained FDA approval to begin phase 2 clinical trials while noting t...
-
Pfizer’s Neuroscience Drugs Sales To Plunge 45% In 2020?
Pfizer’s (NYSE:PFE) Neuroscience Drugs have seen revenues shrink from $6.4 billion in 2017 to $4.1 billion in 2019, and we expect these revenues to decline further in 2020 to around $2.3 billion, reflecting a whopping 44% y-o-y decline, as we det...
-
Buy, Sell, Or Hold Pfizer At $37?
Pfizer (NYSE:PFE) stock declined 4% from $39 in the beginning of this year to $37 as of April 24, compared to over a 10% decline for the broader S&P 500. While Pfizer stock has outperformed the broader markets, we believe there is close to 20...
-
Sell Pfizer To Buy Merck?
Based on historical performance, Pfizer (NYSE:PFE) appears to be less attractive compared to Merck (NYSE:MRK) in the current crisis. The current coronavirus crisis will likely impact pharmaceutical companies on two fronts, 1. supply chain disrup...
